img

Global Multiple Sclerosis (MS) Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Multiple Sclerosis (MS) Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Multiple Sclerosis (MS) Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Multiple Sclerosis (MS) Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from RRMS and SPMS are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Multiple Sclerosis (MS) Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Multiple Sclerosis (MS) Drugs key manufacturers include Bayer AG, Bayhill Therapeutics, Biogen Idec, Cinnagen, Daiichi Sankyo, Eli Lilly, Fast Forward Llc, Antisense Therapeutics and Apitope, etc. Bayer AG, Bayhill Therapeutics, Biogen Idec are top 3 players and held % sales share in total in 2022.
Multiple Sclerosis (MS) Drugs can be divided into Copaxone (Glatiramer Acetate, Copolymer 1), Novantrone (Mitoxantrone), Gilenya (Fingolimod, Fty720) and Aubagio (Teriflunomide), etc. Copaxone (Glatiramer Acetate, Copolymer 1) is the mainstream product in the market, accounting for % sales share globally in 2022.
Multiple Sclerosis (MS) Drugs is widely used in various fields, such as RRMS, SPMS, PPMS and PRMS, etc. RRMS provides greatest supports to the Multiple Sclerosis (MS) Drugs industry development. In 2022, global % sales of Multiple Sclerosis (MS) Drugs went into RRMS filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Multiple Sclerosis (MS) Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Bayer AG
Bayhill Therapeutics
Biogen Idec
Cinnagen
Daiichi Sankyo
Eli Lilly
Fast Forward Llc
Antisense Therapeutics
Apitope
Five Prime Therapeutics
Genmab
Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics
Segment by Type
Copaxone (Glatiramer Acetate, Copolymer 1)
Novantrone (Mitoxantrone)
Gilenya (Fingolimod, Fty720)
Aubagio (Teriflunomide)
Tecfidera (Dimethyl Fumarate)
Firategrast (Sb683699, T-0047)
Siponimod (Baf312)
Others

Segment by Application


RRMS
SPMS
PPMS
PRMS

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Multiple Sclerosis (MS) Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Multiple Sclerosis (MS) Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Multiple Sclerosis (MS) Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Multiple Sclerosis (MS) Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Multiple Sclerosis (MS) Drugs introduction, etc. Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Multiple Sclerosis (MS) Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 Multiple Sclerosis (MS) Drugs Market Overview
1.1 Multiple Sclerosis (MS) Drugs Product Overview
1.2 Multiple Sclerosis (MS) Drugs Market Segment by Type
1.2.1 Copaxone (Glatiramer Acetate, Copolymer 1)
1.2.2 Novantrone (Mitoxantrone)
1.2.3 Gilenya (Fingolimod, Fty720)
1.2.4 Aubagio (Teriflunomide)
1.2.5 Tecfidera (Dimethyl Fumarate)
1.2.6 Firategrast (Sb683699, T-0047)
1.2.7 Siponimod (Baf312)
1.2.8 Others
1.3 Global Multiple Sclerosis (MS) Drugs Market Size by Type
1.3.1 Global Multiple Sclerosis (MS) Drugs Market Size Overview by Type (2018-2034)
1.3.2 Global Multiple Sclerosis (MS) Drugs Historic Market Size Review by Type (2018-2024)
1.3.3 Global Multiple Sclerosis (MS) Drugs Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Multiple Sclerosis (MS) Drugs Sales Breakdown by Type (2018-2024)
1.4.2 Europe Multiple Sclerosis (MS) Drugs Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Multiple Sclerosis (MS) Drugs Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Breakdown by Type (2018-2024)
2 Global Multiple Sclerosis (MS) Drugs Market Competition by Company
2.1 Global Top Players by Multiple Sclerosis (MS) Drugs Sales (2018-2024)
2.2 Global Top Players by Multiple Sclerosis (MS) Drugs Revenue (2018-2024)
2.3 Global Top Players by Multiple Sclerosis (MS) Drugs Price (2018-2024)
2.4 Global Top Manufacturers Multiple Sclerosis (MS) Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Multiple Sclerosis (MS) Drugs Market Competitive Situation and Trends
2.5.1 Multiple Sclerosis (MS) Drugs Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Multiple Sclerosis (MS) Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Multiple Sclerosis (MS) Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Multiple Sclerosis (MS) Drugs Market
2.8 Key Manufacturers Multiple Sclerosis (MS) Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Multiple Sclerosis (MS) Drugs Status and Outlook by Region
3.1 Global Multiple Sclerosis (MS) Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Multiple Sclerosis (MS) Drugs Historic Market Size by Region
3.2.1 Global Multiple Sclerosis (MS) Drugs Sales in Volume by Region (2018-2024)
3.2.2 Global Multiple Sclerosis (MS) Drugs Sales in Value by Region (2018-2024)
3.2.3 Global Multiple Sclerosis (MS) Drugs Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Multiple Sclerosis (MS) Drugs Forecasted Market Size by Region
3.3.1 Global Multiple Sclerosis (MS) Drugs Sales in Volume by Region (2024-2034)
3.3.2 Global Multiple Sclerosis (MS) Drugs Sales in Value by Region (2024-2034)
3.3.3 Global Multiple Sclerosis (MS) Drugs Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Multiple Sclerosis (MS) Drugs by Application
4.1 Multiple Sclerosis (MS) Drugs Market Segment by Application
4.1.1 RRMS
4.1.2 SPMS
4.1.3 PPMS
4.1.4 PRMS
4.2 Global Multiple Sclerosis (MS) Drugs Market Size by Application
4.2.1 Global Multiple Sclerosis (MS) Drugs Market Size Overview by Application (2018-2034)
4.2.2 Global Multiple Sclerosis (MS) Drugs Historic Market Size Review by Application (2018-2024)
4.2.3 Global Multiple Sclerosis (MS) Drugs Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Multiple Sclerosis (MS) Drugs Sales Breakdown by Application (2018-2024)
4.3.2 Europe Multiple Sclerosis (MS) Drugs Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Multiple Sclerosis (MS) Drugs Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Breakdown by Application (2018-2024)
5 North America Multiple Sclerosis (MS) Drugs by Country
5.1 North America Multiple Sclerosis (MS) Drugs Historic Market Size by Country
5.1.1 North America Multiple Sclerosis (MS) Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Multiple Sclerosis (MS) Drugs Sales in Volume by Country (2018-2024)
5.1.3 North America Multiple Sclerosis (MS) Drugs Sales in Value by Country (2018-2024)
5.2 North America Multiple Sclerosis (MS) Drugs Forecasted Market Size by Country
5.2.1 North America Multiple Sclerosis (MS) Drugs Sales in Volume by Country (2024-2034)
5.2.2 North America Multiple Sclerosis (MS) Drugs Sales in Value by Country (2024-2034)
6 Europe Multiple Sclerosis (MS) Drugs by Country
6.1 Europe Multiple Sclerosis (MS) Drugs Historic Market Size by Country
6.1.1 Europe Multiple Sclerosis (MS) Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Multiple Sclerosis (MS) Drugs Sales in Volume by Country (2018-2024)
6.1.3 Europe Multiple Sclerosis (MS) Drugs Sales in Value by Country (2018-2024)
6.2 Europe Multiple Sclerosis (MS) Drugs Forecasted Market Size by Country
6.2.1 Europe Multiple Sclerosis (MS) Drugs Sales in Volume by Country (2024-2034)
6.2.2 Europe Multiple Sclerosis (MS) Drugs Sales in Value by Country (2024-2034)
7 Asia-Pacific Multiple Sclerosis (MS) Drugs by Region
7.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Multiple Sclerosis (MS) Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales in Value by Region (2024-2034)
8 Latin America Multiple Sclerosis (MS) Drugs by Country
8.1 Latin America Multiple Sclerosis (MS) Drugs Historic Market Size by Country
8.1.1 Latin America Multiple Sclerosis (MS) Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Multiple Sclerosis (MS) Drugs Sales in Volume by Country (2018-2024)
8.1.3 Latin America Multiple Sclerosis (MS) Drugs Sales in Value by Country (2018-2024)
8.2 Latin America Multiple Sclerosis (MS) Drugs Forecasted Market Size by Country
8.2.1 Latin America Multiple Sclerosis (MS) Drugs Sales in Volume by Country (2024-2034)
8.2.2 Latin America Multiple Sclerosis (MS) Drugs Sales in Value by Country (2024-2034)
9 Middle East and Africa Multiple Sclerosis (MS) Drugs by Country
9.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Bayer AG
10.1.1 Bayer AG Company Information
10.1.2 Bayer AG Introduction and Business Overview
10.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Bayer AG Multiple Sclerosis (MS) Drugs Products Offered
10.1.5 Bayer AG Recent Development
10.2 Bayhill Therapeutics
10.2.1 Bayhill Therapeutics Company Information
10.2.2 Bayhill Therapeutics Introduction and Business Overview
10.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Products Offered
10.2.5 Bayhill Therapeutics Recent Development
10.3 Biogen Idec
10.3.1 Biogen Idec Company Information
10.3.2 Biogen Idec Introduction and Business Overview
10.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Biogen Idec Multiple Sclerosis (MS) Drugs Products Offered
10.3.5 Biogen Idec Recent Development
10.4 Cinnagen
10.4.1 Cinnagen Company Information
10.4.2 Cinnagen Introduction and Business Overview
10.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Cinnagen Multiple Sclerosis (MS) Drugs Products Offered
10.4.5 Cinnagen Recent Development
10.5 Daiichi Sankyo
10.5.1 Daiichi Sankyo Company Information
10.5.2 Daiichi Sankyo Introduction and Business Overview
10.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Products Offered
10.5.5 Daiichi Sankyo Recent Development
10.6 Eli Lilly
10.6.1 Eli Lilly Company Information
10.6.2 Eli Lilly Introduction and Business Overview
10.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Eli Lilly Multiple Sclerosis (MS) Drugs Products Offered
10.6.5 Eli Lilly Recent Development
10.7 Fast Forward Llc
10.7.1 Fast Forward Llc Company Information
10.7.2 Fast Forward Llc Introduction and Business Overview
10.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Products Offered
10.7.5 Fast Forward Llc Recent Development
10.8 Antisense Therapeutics
10.8.1 Antisense Therapeutics Company Information
10.8.2 Antisense Therapeutics Introduction and Business Overview
10.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Products Offered
10.8.5 Antisense Therapeutics Recent Development
10.9 Apitope
10.9.1 Apitope Company Information
10.9.2 Apitope Introduction and Business Overview
10.9.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Apitope Multiple Sclerosis (MS) Drugs Products Offered
10.9.5 Apitope Recent Development
10.10 Five Prime Therapeutics
10.10.1 Five Prime Therapeutics Company Information
10.10.2 Five Prime Therapeutics Introduction and Business Overview
10.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Products Offered
10.10.5 Five Prime Therapeutics Recent Development
10.11 Genmab
10.11.1 Genmab Company Information
10.11.2 Genmab Introduction and Business Overview
10.11.3 Genmab Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Genmab Multiple Sclerosis (MS) Drugs Products Offered
10.11.5 Genmab Recent Development
10.12 Artielle Immunotherapeutics
10.12.1 Artielle Immunotherapeutics Company Information
10.12.2 Artielle Immunotherapeutics Introduction and Business Overview
10.12.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Products Offered
10.12.5 Artielle Immunotherapeutics Recent Development
10.13 Genzyme
10.13.1 Genzyme Company Information
10.13.2 Genzyme Introduction and Business Overview
10.13.3 Genzyme Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.13.4 Genzyme Multiple Sclerosis (MS) Drugs Products Offered
10.13.5 Genzyme Recent Development
10.14 Glaxosmithkline
10.14.1 Glaxosmithkline Company Information
10.14.2 Glaxosmithkline Introduction and Business Overview
10.14.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.14.4 Glaxosmithkline Multiple Sclerosis (MS) Drugs Products Offered
10.14.5 Glaxosmithkline Recent Development
10.15 Gw Pharmaceuticals
10.15.1 Gw Pharmaceuticals Company Information
10.15.2 Gw Pharmaceuticals Introduction and Business Overview
10.15.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.15.4 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Products Offered
10.15.5 Gw Pharmaceuticals Recent Development
10.16 Innate Immunotherapeutics
10.16.1 Innate Immunotherapeutics Company Information
10.16.2 Innate Immunotherapeutics Introduction and Business Overview
10.16.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.16.4 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Products Offered
10.16.5 Innate Immunotherapeutics Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Multiple Sclerosis (MS) Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Multiple Sclerosis (MS) Drugs Industrial Chain Analysis
11.4 Multiple Sclerosis (MS) Drugs Market Dynamics
11.4.1 Multiple Sclerosis (MS) Drugs Industry Trends
11.4.2 Multiple Sclerosis (MS) Drugs Market Drivers
11.4.3 Multiple Sclerosis (MS) Drugs Market Challenges
11.4.4 Multiple Sclerosis (MS) Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Multiple Sclerosis (MS) Drugs Distributors
12.3 Multiple Sclerosis (MS) Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Copaxone (Glatiramer Acetate, Copolymer 1)
Table 2. Major Company of Novantrone (Mitoxantrone)
Table 3. Major Company of Gilenya (Fingolimod, Fty720)
Table 4. Major Company of Aubagio (Teriflunomide)
Table 5. Major Company of Tecfidera (Dimethyl Fumarate)
Table 6. Major Company of Firategrast (Sb683699, T-0047)
Table 7. Major Company of Siponimod (Baf312)
Table 8. Major Company of Others
Table 9. Global Multiple Sclerosis (MS) Drugs Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 10. Global Multiple Sclerosis (MS) Drugs Sales by Type (2018-2024) & (K Pcs)
Table 11. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Type (2018-2024)
Table 12. Global Multiple Sclerosis (MS) Drugs Sales by Type (2018-2024) & (US& Million)
Table 13. Global Multiple Sclerosis (MS) Drugs Market Share in Value by Type (2018-2024)
Table 14. Global Multiple Sclerosis (MS) Drugs Price by Type (2018-2024) & (USD/Pcs)
Table 15. Global Multiple Sclerosis (MS) Drugs Sales by Type (2024-2034) & (K Pcs)
Table 16. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Type (2024-2034)
Table 17. Global Multiple Sclerosis (MS) Drugs Sales by Type (2024-2034) & (US$ Million)
Table 18. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Type (2024-2034)
Table 19. Global Multiple Sclerosis (MS) Drugs Price by Type (2024-2034) & (USD/Pcs)
Table 20. North America Multiple Sclerosis (MS) Drugs Sales by Type (2018-2024) & (K Pcs)
Table 21. North America Multiple Sclerosis (MS) Drugs Sales by Type (2018-2024) & (US$ Million)
Table 22. Europe Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Type (2018-2024)
Table 23. Europe Multiple Sclerosis (MS) Drugs Sales by Type (2018-2024) & (US$ Million)
Table 24. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Type (2018-2024)
Table 25. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales by Type (2018-2024) & (US$ Million)
Table 26. Latin America Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Type (2018-2024)
Table 27. Latin America Multiple Sclerosis (MS) Drugs Sales by Type (2018-2024) & (US$ Million)
Table 28. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Type (2018-2024)
Table 29. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Type (2018-2024) & (US$ Million)
Table 30. Global Multiple Sclerosis (MS) Drugs Sales by Company (2018-2024) & (K Pcs)
Table 31. Global Multiple Sclerosis (MS) Drugs Sales Share by Company (2018-2024)
Table 32. Global Multiple Sclerosis (MS) Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 33. Global Multiple Sclerosis (MS) Drugs Revenue Share by Company (2018-2024)
Table 34. Global Market Multiple Sclerosis (MS) Drugs Price by Company (2018-2024) & (USD/Pcs)
Table 35. Global Multiple Sclerosis (MS) Drugs Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 36. Global Multiple Sclerosis (MS) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 37. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Multiple Sclerosis (MS) Drugs as of 2022)
Table 38. Date of Key Manufacturers Enter into Multiple Sclerosis (MS) Drugs Market
Table 39. Key Manufacturers Multiple Sclerosis (MS) Drugs Product Type
Table 40. Mergers & Acquisitions, Expansion Plans
Table 41. Global Multiple Sclerosis (MS) Drugs Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 42. Global Multiple Sclerosis (MS) Drugs Sales by Region (2018-2024) & (K Pcs)
Table 43. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Region (2018-2024)
Table 44. Global Multiple Sclerosis (MS) Drugs Sales by Region (2018-2024) & (US$ Million)
Table 45. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Region (2018-2024)
Table 46. Global Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 47. Global Multiple Sclerosis (MS) Drugs Sales by Region (2024-2034) & (K Pcs)
Table 48. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Region (2024-2034)
Table 49. Global Multiple Sclerosis (MS) Drugs Sales by Region (2024-2034) & (US$ Million)
Table 50. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Region (2024-2034)
Table 51. Global Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2024-2034)
Table 52. Global Multiple Sclerosis (MS) Drugs Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 53. Global Multiple Sclerosis (MS) Drugs Sales by Application (2018-2024) & (K Pcs)
Table 54. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Application (2018-2024)
Table 55. Global Multiple Sclerosis (MS) Drugs Sales by Application (2018-2024) & (US$ Million)
Table 56. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Application (2018-2024)
Table 57. Global Multiple Sclerosis (MS) Drugs Price by Application (2018-2024) & (USD/Pcs)
Table 58. Global Multiple Sclerosis (MS) Drugs Sales by Application (2024-2034) & (K Pcs)
Table 59. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Application (2024-2034)
Table 60. Global Multiple Sclerosis (MS) Drugs Sales by Application (2024-2034) & (US$ Million)
Table 61. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Application (2024-2034)
Table 62. Global Multiple Sclerosis (MS) Drugs Price by Application (2024-2034) & (USD/Pcs)
Table 63. North America Multiple Sclerosis (MS) Drugs Sales by Application (2018-2024) (K Pcs)
Table 64. North America Multiple Sclerosis (MS) Drugs Sales by Application (2018-2024) & (US$ Million)
Table 65. Europe Multiple Sclerosis (MS) Drugs Sales by Application (2018-2024) (K Pcs)
Table 66. Europe Multiple Sclerosis (MS) Drugs Sales by Application (2018-2024) & (US$ Million)
Table 67. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales by Application (2018-2024) (K Pcs)
Table 68. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales by Application (2018-2024) & (US$ Million)
Table 69. Latin America Multiple Sclerosis (MS) Drugs Sales by Application (2018-2024) (K Pcs)
Table 70. Latin America Multiple Sclerosis (MS) Drugs Sales by Application (2018-2024) & (US$ Million)
Table 71. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Application (2018-2024) (K Pcs)
Table 72. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Application (2018-2024) & (US$ Million)
Table 73. North America Multiple Sclerosis (MS) Drugs Sales by Country (2018-2024) & (K Pcs)
Table 74. North America Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Country (2018-2024)
Table 75. North America Multiple Sclerosis (MS) Drugs Sales by Country (2018-2024) & (US$ Million)
Table 76. North America Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Country (2018-2024)
Table 77. North America Multiple Sclerosis (MS) Drugs Sales by Country (2024-2034) & (K Pcs)
Table 78. North America Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Country (2024-2034)
Table 79. North America Multiple Sclerosis (MS) Drugs Sales by Country (2024-2034) & (US$ Million)
Table 80. North America Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Country (2024-2034)
Table 81. Europe Multiple Sclerosis (MS) Drugs Sales by Country (2018-2024) & (K Pcs)
Table 82. Europe Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Country (2018-2024)
Table 83. Europe Multiple Sclerosis (MS) Drugs Sales by Country (2018-2024) & (US$ Million)
Table 84. Europe Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Country (2018-2024)
Table 85. Europe Multiple Sclerosis (MS) Drugs Sales by Country (2024-2034) & (K Pcs)
Table 86. Europe Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Country (2024-2034)
Table 87. Europe Multiple Sclerosis (MS) Drugs Sales by Country (2024-2034) & (US$ Million)
Table 88. Europe Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Country (2024-2034)
Table 89. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales by Region (2018-2024) & (K Pcs)
Table 90. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Region (2018-2024)
Table 91. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales by Region (2018-2024) & (US$ Million)
Table 92. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Region (2018-2024)
Table 93. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales by Region (2024-2034) & (K Pcs)
Table 94. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Region (2024-2034)
Table 95. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales by Region (2024-2034) & (US$ Million)
Table 96. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Region (2024-2034)
Table 97. Latin America Multiple Sclerosis (MS) Drugs Sales by Country (2018-2024) & (K Pcs)
Table 98. Latin America Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Country (2018-2024)
Table 99. Latin America Multiple Sclerosis (MS) Drugs Sales by Country (2018-2024) & (US$ Million)
Table 100. Latin America Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Country (2018-2024)
Table 101. Latin America Multiple Sclerosis (MS) Drugs Sales by Country (2024-2034) & (K Pcs)
Table 102. Latin America Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Country (2024-2034)
Table 103. Latin America Multiple Sclerosis (MS) Drugs Sales by Country (2024-2034) & (US$ Million)
Table 104. Latin America Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Country (2024-2034)
Table 105. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country (2018-2024) & (K Pcs)
Table 106. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Country (2018-2024)
Table 107. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country (2018-2024) & (US$ Million)
Table 108. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Country (2018-2024)
Table 109. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country (2024-2034) & (K Pcs)
Table 110. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Country (2024-2034)
Table 111. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country (2024-2034) & (US$ Million)
Table 112. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Country (2024-2034)
Table 113. Bayer AG Company Information
Table 114. Bayer AG Introduction and Business Overview
Table 115. Bayer AG Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 116. Bayer AG Multiple Sclerosis (MS) Drugs Product
Table 117. Bayer AG Recent Development
Table 118. Bayhill Therapeutics Company Information
Table 119. Bayhill Therapeutics Introduction and Business Overview
Table 120. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 121. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product
Table 122. Bayhill Therapeutics Recent Development
Table 123. Biogen Idec Company Information
Table 124. Biogen Idec Introduction and Business Overview
Table 125. Biogen Idec Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 126. Biogen Idec Multiple Sclerosis (MS) Drugs Product
Table 127. Biogen Idec Recent Development
Table 128. Cinnagen Company Information
Table 129. Cinnagen Introduction and Business Overview
Table 130. Cinnagen Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 131. Cinnagen Multiple Sclerosis (MS) Drugs Product
Table 132. Cinnagen Recent Development
Table 133. Daiichi Sankyo Company Information
Table 134. Daiichi Sankyo Introduction and Business Overview
Table 135. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 136. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product
Table 137. Daiichi Sankyo Recent Development
Table 138. Eli Lilly Company Information
Table 139. Eli Lilly Introduction and Business Overview
Table 140. Eli Lilly Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 141. Eli Lilly Multiple Sclerosis (MS) Drugs Product
Table 142. Eli Lilly Recent Development
Table 143. Fast Forward Llc Company Information
Table 144. Fast Forward Llc Introduction and Business Overview
Table 145. Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 146. Fast Forward Llc Multiple Sclerosis (MS) Drugs Product
Table 147. Fast Forward Llc Recent Development
Table 148. Antisense Therapeutics Company Information
Table 149. Antisense Therapeutics Introduction and Business Overview
Table 150. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 151. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product
Table 152. Antisense Therapeutics Recent Development
Table 153. Apitope Company Information
Table 154. Apitope Introduction and Business Overview
Table 155. Apitope Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 156. Apitope Multiple Sclerosis (MS) Drugs Product
Table 157. Apitope Recent Development
Table 158. Five Prime Therapeutics Company Information
Table 159. Five Prime Therapeutics Introduction and Business Overview
Table 160. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 161. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product
Table 162. Five Prime Therapeutics Recent Development
Table 163. Genmab Company Information
Table 164. Genmab Introduction and Business Overview
Table 165. Genmab Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 166. Genmab Multiple Sclerosis (MS) Drugs Product
Table 167. Genmab Recent Development
Table 168. Artielle Immunotherapeutics Company Information
Table 169. Artielle Immunotherapeutics Introduction and Business Overview
Table 170. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 171. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product
Table 172. Artielle Immunotherapeutics Recent Development
Table 173. Genzyme Company Information
Table 174. Genzyme Introduction and Business Overview
Table 175. Genzyme Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 176. Genzyme Multiple Sclerosis (MS) Drugs Product
Table 177. Genzyme Recent Development
Table 178. Glaxosmithkline Company Information
Table 179. Glaxosmithkline Introduction and Business Overview
Table 180. Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 181. Glaxosmithkline Multiple Sclerosis (MS) Drugs Product
Table 182. Glaxosmithkline Recent Development
Table 183. Gw Pharmaceuticals Company Information
Table 184. Gw Pharmaceuticals Introduction and Business Overview
Table 185. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 186. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product
Table 187. Gw Pharmaceuticals Recent Development
Table 188. Innate Immunotherapeutics Company Information
Table 189. Innate Immunotherapeutics Introduction and Business Overview
Table 190. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 191. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product
Table 192. Innate Immunotherapeutics Recent Development
Table 193. Key Raw Materials Lists
Table 194. Raw Materials Key Suppliers Lists
Table 195. Multiple Sclerosis (MS) Drugs Market Trends
Table 196. Multiple Sclerosis (MS) Drugs Market Drivers
Table 197. Multiple Sclerosis (MS) Drugs Market Challenges
Table 198. Multiple Sclerosis (MS) Drugs Market Restraints
Table 199. Multiple Sclerosis (MS) Drugs Distributors List
Table 200. Multiple Sclerosis (MS) Drugs Downstream Customers
Table 201. Research Programs/Design for This Report
Table 202. Key Data Information from Secondary Sources
Table 203. Key Data Information from Primary Sources
List of Figures
Figure 1. Multiple Sclerosis (MS) Drugs Product Picture
Figure 2. Global Multiple Sclerosis (MS) Drugs Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Multiple Sclerosis (MS) Drugs Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Multiple Sclerosis (MS) Drugs Sales Status and Outlook (2018-2034) & (K Pcs)
Figure 5. Product Picture of Copaxone (Glatiramer Acetate, Copolymer 1)
Figure 6. Global Copaxone (Glatiramer Acetate, Copolymer 1) Sales YoY Growth (2018-2034) & (K Pcs)
Figure 7. Product Picture of Novantrone (Mitoxantrone)
Figure 8. Global Novantrone (Mitoxantrone) Sales YoY Growth (2018-2034) & (K Pcs)
Figure 9. Product Picture of Gilenya (Fingolimod, Fty720)
Figure 10. Global Gilenya (Fingolimod, Fty720) Sales YoY Growth (2018-2034) & (K Pcs)
Figure 11. Product Picture of Aubagio (Teriflunomide)
Figure 12. Global Aubagio (Teriflunomide) Sales YoY Growth (2018-2034) & (K Pcs)
Figure 13. Product Picture of Tecfidera (Dimethyl Fumarate)
Figure 14. Global Tecfidera (Dimethyl Fumarate) Sales YoY Growth (2018-2034) & (K Pcs)
Figure 15. Product Picture of Firategrast (Sb683699, T-0047)
Figure 16. Global Firategrast (Sb683699, T-0047) Sales YoY Growth (2018-2034) & (K Pcs)
Figure 17. Product Picture of Siponimod (Baf312)
Figure 18. Global Siponimod (Baf312) Sales YoY Growth (2018-2034) & (K Pcs)
Figure 19. Product Picture of Others
Figure 20. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 21. Global Multiple Sclerosis (MS) Drugs Sales by Type (2018-2034) & (US$ Million)
Figure 22. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type in 2022 & 2034
Figure 23. North America Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Type in 2022
Figure 24. North America Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Type in 2022
Figure 25. Europe Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Type in 2022
Figure 26. Europe Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Type in 2022
Figure 27. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Type in 2022
Figure 28. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Type in 2022
Figure 29. Latin America Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Type in 2022
Figure 30. Latin America Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Type in 2022
Figure 31. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Type in 2022
Figure 32. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Type in 2022
Figure 33. The 5 and 10 Largest Manufacturers in the World: Market Share by Multiple Sclerosis (MS) Drugs Sales in 2022
Figure 34. The 5 and 10 Largest Manufacturers in the World: Market Share by Multiple Sclerosis (MS) Drugs Revenue in 2022
Figure 35. Multiple Sclerosis (MS) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 36. Product Picture of RRMS
Figure 37. Global RRMS Sales YoY Growth (2018-2034) & (K Pcs)
Figure 38. Product Picture of SPMS
Figure 39. Global SPMS Sales YoY Growth (2018-2034) & (K Pcs)
Figure 40. Product Picture of PPMS
Figure 41. Global PPMS Sales YoY Growth (2018-2034) & (K Pcs)
Figure 42. Product Picture of PRMS
Figure 43. Global PRMS Sales YoY Growth (2018-2034) & (K Pcs)
Figure 44. Global Multiple Sclerosis (MS) Drugs Sales by Application (2018-2034) & (US$ Million)
Figure 45. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application in 2022 & 2034
Figure 46. North America Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Application in 2022
Figure 47. North America Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Application in 2022
Figure 48. Europe Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Application in 2022
Figure 49. Europe Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Application in 2022
Figure 50. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Application in 2022
Figure 51. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Application in 2022
Figure 52. Latin America Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Application in 2022
Figure 53. Latin America Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Application in 2022
Figure 54. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Application in 2022
Figure 55. Key Raw Materials Price
Figure 56. Multiple Sclerosis (MS) Drugs Manufacturing Cost Structure
Figure 57. Multiple Sclerosis (MS) Drugs Industrial Chain Analysis
Figure 58. Channels of Distribution
Figure 59. Distributors Profiles
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries